FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361025669> ?p ?o ?g. }

• W4361025669 abstract "Back to table of contents Previous article Next article Annual MeetingFull AccessExperts to Discuss the Ethics of PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:27 Mar 2023https://doi.org/10.1176/appi.pn.2023.04.3.10AbstractA session at APA’s Annual Meeting will cover the current state of psychedelics research and offer points to consider in the event of broad psychedelics decriminalization and legalization.As more and more states consider decriminalizing or legalizing psychedelics, chances are at least some of your patients are curious about whether psychedelics could help them. A session titled “Ethical and Practical Implications of Psychedelics in Psychiatry” at APA’s Annual Meeting in May will prepare you for your patients’ questions and provide you with the knowledge you need to make appropriate decisions regarding the use of psychedelic therapy.The psychological effects of psychedelics raise novel ethical concerns surrounding such issues as informed consent and patient vulnerability, said Gregory Samuel Barber, M.D.“Psilocybin, MDMA, and other psychedelic-assisted psychotherapies involve treatment paradigms that in many ways are unique from current psychiatric treatments,” said session chair Gregory Samuel Barber, M.D., a psychiatrist and psychotherapist in private practice in Bethesda, Md. “The intense and acute psychological effects of psychedelics raise novel ethical concerns surrounding issues like informed consent and patient vulnerability, while their resource and time intensiveness pose challenges to matters of equity and access. We hope that this talk will spur psychiatrists into conversation about how to ensure that psychedelic treatments are offered safely, effectively, and ethically.”In the session, members of APA’s Council on Addictions and the American Indian, Alaska Native, and Native Hawaiian Caucus will join members of APA’s Ethics Committee to discuss emerging ethical and practical issues in the field of psychedelic-assisted psychotherapy. The panel will discuss ethical challenges surrounding psychedelics in their current investigational stage, as well as issues for psychiatrists to consider if psychedelics one day become available for broad clinical use. The discussion will cover research equipoise (the state of genuine uncertainty on the part of the clinical investigator regarding the comparative therapeutic merits of each arm in a trial), informed consent, patient vulnerability, equity and access, and “psychedelic self-enhancement.”“The future success of psychedelic therapies depends in large part on ensuring that they are used ethically, that psychiatrists understand their limitations, and that patients and the public believe that mental health professionals are using them responsibly,” Barber told Psychiatric News. ■ ISSUES NewArchived" @default.
• W4361025669 created "2023-03-30" @default.
• W4361025669 creator A5056763663 @default.
• W4361025669 date "2023-04-01" @default.
• W4361025669 modified "2023-09-27" @default.
• W4361025669 title "Experts to Discuss the Ethics of Psychedelics" @default.
• W4361025669 doi "https://doi.org/10.1176/appi.pn.2023.04.3.10" @default.
• W4361025669 hasPublicationYear "2023" @default.
• W4361025669 type Work @default.
• W4361025669 citedByCount "0" @default.
• W4361025669 crossrefType "journal-article" @default.
• W4361025669 hasAuthorship W4361025669A5056763663 @default.
• W4361025669 hasConcept C118552586 @default.
• W4361025669 hasConcept C124315065 @default.
• W4361025669 hasConcept C136764020 @default.
• W4361025669 hasConcept C15744967 @default.
• W4361025669 hasConcept C2776502132 @default.
• W4361025669 hasConcept C2777200299 @default.
• W4361025669 hasConcept C2778506969 @default.
• W4361025669 hasConcept C2779182362 @default.
• W4361025669 hasConcept C38652104 @default.
• W4361025669 hasConcept C41008148 @default.
• W4361025669 hasConcept C46312422 @default.
• W4361025669 hasConcept C542102704 @default.
• W4361025669 hasConcept C95713431 @default.
• W4361025669 hasConceptScore W4361025669C118552586 @default.
• W4361025669 hasConceptScore W4361025669C124315065 @default.
• W4361025669 hasConceptScore W4361025669C136764020 @default.
• W4361025669 hasConceptScore W4361025669C15744967 @default.
• W4361025669 hasConceptScore W4361025669C2776502132 @default.
• W4361025669 hasConceptScore W4361025669C2777200299 @default.
• W4361025669 hasConceptScore W4361025669C2778506969 @default.
• W4361025669 hasConceptScore W4361025669C2779182362 @default.
• W4361025669 hasConceptScore W4361025669C38652104 @default.
• W4361025669 hasConceptScore W4361025669C41008148 @default.
• W4361025669 hasConceptScore W4361025669C46312422 @default.
• W4361025669 hasConceptScore W4361025669C542102704 @default.
• W4361025669 hasConceptScore W4361025669C95713431 @default.
• W4361025669 hasIssue "04" @default.
• W4361025669 hasLocation W43610256691 @default.
• W4361025669 hasOpenAccess W4361025669 @default.
• W4361025669 hasPrimaryLocation W43610256691 @default.
• W4361025669 hasRelatedWork W2043786589 @default.
• W4361025669 hasRelatedWork W2133206039 @default.
• W4361025669 hasRelatedWork W2466492684 @default.
• W4361025669 hasRelatedWork W2914523691 @default.
• W4361025669 hasRelatedWork W3157248359 @default.
• W4361025669 hasRelatedWork W3183684219 @default.
• W4361025669 hasRelatedWork W4225369986 @default.
• W4361025669 hasRelatedWork W4281568156 @default.
• W4361025669 hasRelatedWork W4283331022 @default.
• W4361025669 hasRelatedWork W4385898071 @default.
• W4361025669 hasVolume "58" @default.
• W4361025669 isParatext "false" @default.
• W4361025669 isRetracted "false" @default.
• W4361025669 workType "article" @default.